Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global subcutaneous biologics market is projected to register significant growth over the forecast period from 2020 to 2030.
Subcutaneous Biologics to Remain Most Preferred Treatment for Cancer and Diabetes
Fact.MR’s latest report on subcutaneous biologics market uncovers the growth projections across leading regions. It also discusses in detail, various growth drivers, restraints, latest trends and emerging opportunities affecting the market dynamics. The report has been segmented on the basis of indication, delivery system, distribution channel and region.
Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global subcutaneous biologics market is projected to register significant growth over the forecast period from 2020 to 2030.
The swift expansion of subcutaneous biologics market is attributed to the increasing prevalence of chronic diseases, rising consumer spending on medicines and rapid advancements in biotechnology.
Subcutaneous biologics have emerged as the most advanced therapeutics, used for the treatment of multiple diseases such as cancer and diabetes. Administration of biologics through subcutaneous mode is highly preferred due to its easy, safer, and cost-effective nature.
Rising cases of chronic diseases is a major factor driving the subcutaneous biologics market. According to the International Diabetes Federation (IDF), an estimated 537 million adults are living with diabetes worldwide (2021).
To manage and curb this global burden, insulin shots are being taken on large scales. This is positively impacting the growth of subcutaneous biologics market.
Further, rising trend of self-medication has completely transformed the subcutaneous biologics market. Adoption of user-friendly delivery systems is gaining traction. People are purchasing wearable and automatic injections to cut down the healthcare costs.
For More Valuable Information on Market Dynamics, Request a Report Brochure
https://www.factmr.com/connectus/sample?flag=B&rep_id=5283
Moreover, growing health awareness, continuous product approvals and increasing penetration of subcutaneous biologics across developing regions are anticipated to boost the growth of global market through 2030.
As per Fact.MR, subcutaneous biologics will remain the most preferred treatment for cancer and diabetes. This can be attributed to the rising cases of cancer and diabetes worldwide. As continuous biologic drug shots are required to manage cancer and diabetes, people are opting for self-delivery drug systems.
Regionally, North America will continue to dominate the subcutaneous biologics market during the forecast period. Growth in the region is attributed to highly established biopharmaceutical industry, rising trend of self-medication and increasing prevalence of chronic diseases.
“Increasing spending by consumers on purchasing self-care delivery systems is creating lucrative growth avenues within subcutaneous biologics market. In order to capitalize on this trend, key players are introducing user-friendly products such as wearable and automatic injectors,” says a Fact.MR analyst
Key Takeaways from Subcutaneous Biologics Market Survey
- The U.S. is anticipated to lead the North America subcutaneous biologics market on account of higher rate of development and commercialization of pharmaceutical products.
- With rising geriatric population and higher patient pool suffering from chronic disorders, the U.K. will emerge as a lucrative market for subcutaneous biologics market over the forecast period.
- China is slated to register strong growth as a result of increasing penetration of domestic market players and rising government support.
- By indication, cancer and diabetes segments are anticipated to account for the largest market share through 2030.
- In terms of delivery system, automatic injectors segment will lead the market over the forecast period.
- Based on distribution channel, hospital pharmacies are anticipated to account for major revenue share through 2030.
Key Drivers
- Rising geriatric population coupled with increasing prevalence of chronic disorders is primarily driving the subcutaneous biologics market.
- Growing trend of self-medications is boosting the sales of subcutaneous biologics and the trend is likely to continue in the future.
- Expansion of biopharmaceutical industry across the globe is positively impacting the subcutaneous biologics market.
Key Restraints
- Side effects associated with some biologics is restraining the growth in the market.
- Stringent regulatory approval may also limit the growth in the market.
For Critical Insights on the Subcutaneous Biologics Market, Request for Methodology here
https://www.factmr.com/connectus/sample?flag=RM&rep_id=5283
Competitive Landscape
Leading players operating in the subcutaneous biologics market are investing in research and development activities for enhancing their product portfolio's. Besides this, they have adopted various growth strategies such as new drug development & approvals, acquisitions, partnerships and establishment of new facilities to gain a competitive edge in the global market.
- In November 2021, BD, a leading global medical technology company announced the launch of a new high tech manufacturing facility in Zaragoza, Spain to supply the European market with pre-filled syringes for use in applications such as vaccines and biologics.
- In July 2020, Celltrion Healthcare announced that the European Commission (EC) granted marketing authorization for Remisima (infliximab CT-P13) subcutaneous formulation for the treatment of adult patients suffering from ankylosing spondylitis, Crohn's disease, psoriasis, and other diseases.
- In November 2021, Pion Inc., leading provider of analytic instruments, launched the SCISSOR N3, its new subcutaneous injection site simulator. The new N3 assesses the risk and performance of subcutaneously administrated drugs including biologics by simulating physiological conditions.
- In December 2020, BD, announced the result from 52-subject human clinical trial with the BD Libertas wearable Injector. The results showed that BD Libertas Wearable Injector effectively delivers dose volumes up to 5 ml subcutaneously.
- In October 2021, BD, launched the new BD SCF PremiumCoat plunger stopper in partnership with Aptar Pharma. The new product is a syringe plunger stopper designed to support the injection of biologics into subcutaneous tissue with a 1 mL pre-filled syringe.
Some of the prominent players operating in the subcutaneous biologics market profiled by Fact.MR are:
- Abbott Laboratories
- Pfizer Inc.
- Genentech Inc.
- Novartis AG
- Biogen Idec
- AbbVie, Inc.
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb
- Eisai, Inc.
- Takeda Pharmaceuticals Ltd.
- Alnylam Pharmaceuticals
- Bayer AG
- GlaxoSmithKline
- Sanofi S.A.
- Boston Pharmaceuticals
- Others.
More Insights on the Global Subcutaneous Biologics Sales Outlook
Fact.MR provides an unbiased analysis of Subcutaneous biologics market, presenting historical demand data (2015-2019) and forecast statistics for the period from 2020-2030. The study divulges compelling insights on the global demand for Subcutaneous biologics with a detailed segmentation on the basis of:
Indication:
- Cancer
- Crohn’s disease
- Cardiovascular disorders
- Diabetes
- Multiple sclerosis
- Psoriasis
- Rheumatoid Arthritis
- Metabolic disorders
- Growth hormone deficiency
- Others
Delivery System:
- Syringe
- Wearable injector
- Automatic injector
- Implants
- Pen injectors
- Others
Distribution Channel:
- Hospital pharmacies
- Retail pharmacies
- Drug stores
- Online pharmacies
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Key Questions Covered in the Subcutaneous Biologics Market Outlook Report
- The report offers insight into subcutaneous biologics demand outlook for 2020-2030
- The market study also highlights projected sales growth for subcutaneous biologics market between 2020 and 2030
- Subcutaneous biologics market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Subcutaneous biologics market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
Biologic Injectors Market Analysis - Over the projected period, the growing demand for drug delivery is expected to be the primary driver of the biologic injectors market. The market for biologic injectors is predicted to develop due to the introduction of disposable and reusable biologic injectors. The prevalence of cancer, brain illnesses, and heart diseases is rising, which is propelling the biologic injectors market forward. As a result, the revenue share of the biologic injectors market is predicted to grow.
Inhalable Biologics Market Scope - The market for inhalable biologics is predicted to develop as the prevalence of chronic diseases rises. Inhalable biologics aid in the treatment of a variety of lung illnesses. These inhalable biologics help minimize medication time and deliver the optimum results to the target locations. The market for inhalable biologics has grown considerably in recent years as a result of these factors. The market is also driven by continuous efforts in inhalable biologics research and development.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to chemical and materials, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our chemical and materials research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR